Neurotechnology Industry Report Says Revenues Grew 10% to $120.5 Billion in 2006; U.S. Economic Impact of Brain-related Illness Reached $1 Trillion
Last week NeuroInsights released our third annual report on neurotech. Unveiled during the annual Neurotechnology Industry Conference, The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is a market analysis and strategic investment guide of the global neurological disease and psychiatric illness markets. This year's 350 page report focuses on the more than 500 public and private companies translating advances in neuroscience into tomorrow’s treatments.
It provides insight and analysis of issues such as corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry. The report provides an in-depth look at fifteen brain and central nervous system disorders, including Alzheimer’s disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, memory decline, obesity, pain, Parkinson’s, psychiatric disorders, stroke and other brain-related illnesses.
Specific findings from the Neurotechnology Industry 2007 Report include:
• Brain-related illnesses afflict more than two billion people worldwide
• The worldwide economic burden of this problem has reached more than $2 trillion per year; more than $1 trillion in the U.S. alone
• 2006 venture capital investment in neurotechnology rose 7.5% to $1.666 billion
• Neurotech industry revenues rose 10% in 2006 to $120.5 billion; this includes neuropharmaceutical revenues of $101 billion, neurodevice revenues of $4.5 billion, neurodiagnostic revenues of $15 billion
• The Neurotech Index of publicly-traded neurotechnology companies was up 53% from its December 31, 2003 conception to March 31, 2006, outpacing the NASDAQ Biotech Index which gained 7% during the same period
Neurotechnology is still very much a frontier industry. In the past year we’ve reached some important milestones, including formation of NIO, the first industry organization devoted to the specific needs of neurotechnology companies. 2006 was also a tremendous year of growth for the industry, and 2007 looks to continue this trend so as technologies improve and our collective body of knowledge grows. Countless opportunities exist as visionary researchers tackle the complexities of brain-related health and visionary companies, organizations and policy makers address the complexities of bringing those discoveries to the billions of people suffering from brain-related illnesses.
If you are seeking funding, new strategic partnerships, or new investment opportunities, You should purchase this report. It was written for you.